Q301--NEW | Automated Blood Bank Solid Phase Analyzer and Associated Reagents/Consumables

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NETWORK CONTRACT OFFICE 19 (36C259)

Contract Value

Not provided

Codes & Classification
Solicitation Number

36C25927Q0058

NAICS

334516 - Analytical Laboratory Instrument Manufacturing

Classification Code

Q301

Additional Details
Set Aside

None

Place of Performance

Aurora, CO, UNITED STATES

SourceSAM
Documents1
The Department of Veterans Affairs (VA), through its Veterans Health Administration (VHA) and Network Contracting Office 19 (NCO 19), has issued a Sources Sought Notice (Procurement Identifier: 36C25927Q0058) to identify potential sources for an instrument rental reagent agreement for an Automated Blood Bank Solid Phase Analyzer and associated reagents/consumables. This market research effort is intended to support the Rocky Mountain Regional VA Medical Center (RMRVAMC) in Aurora, Colorado, and is not a solicitation or request for proposal. The information gathered will inform future procurement planning and does not obligate the government to issue a solicitation or make an award. **Purpose and Scope** The primary objective of this procurement is to secure a new, state-of-the-art Automated Blood Bank Solid Phase Analyzer system, along with all necessary reagents and consumables, to support the RMRVAMC’s transfusion medicine operations. The system must be capable of performing a comprehensive suite of blood bank tests, including but not limited to ABO/Rh typing, antibody screening and identification, antigen phenotyping, direct antiglobulin testing (DAT), and crossmatching donor units with patient samples. The analyzer must also be able to process challenging specimen types, such as rouleaux, lipemic, icteric, and hemolyzed samples, ensuring reliable and accurate results under a variety of clinical conditions. **Key Requirements and Deliverables** - **System Specifications:** The analyzer must be new and in current production; remanufactured or discontinued models are not acceptable. It must deliver accurate, reproducible assays using FDA-approved in vitro diagnostic methods and maintain a monthly uptime of at least 95%. - **Testing Capabilities:** The system must support a wide range of antibody identifications (including Anti-E, Anti-e, Anti-C, Anti-c, Anti-K, Anti-k, Anti-D, and others) and antigen phenotyping, as well as perform crossmatching and direct antiglobulin tests. - **Operational Features:** The analyzer should include an automated cell washer (with a wash cycle under 5 minutes), a centrifuge with automatic load/unload, a printer with necessary replacements, and an incubator capable of simultaneous multiple runs. The turnaround time for a Type & Screen must not exceed 26 minutes. - **Quality Control:** A robust quality control program is required, featuring editable QC files, on-board QC data storage and reporting, DVD data archiving, operator alerts for QC failures, and daily QC performance within 30 minutes. - **Maintenance and Support:** Respondents must detail the hands-on maintenance time required for daily, weekly, monthly, and as-needed tasks, specifying which are user-level and which are service-level. All hardware and software upgrades must be provided at no additional cost and installed within 60 days of commercial release. An uninterruptible power supply (UPS) must be included and maintained by the contractor. - **Reagents and Consumables:** A monthly standing order for routine cell suspension reagents is required. All reagents must be compatible with manual tube testing to ensure continuity of operations during analyzer downtime; if not, a backup analyzer must be provided. - **Facility Integration:** The system must fit within the existing space at the RMRVAMC and be capable of producing results at the manufacturer’s maximum throughput without excessive malfunctions or service interruptions. **Contracting and Administrative Details** - **Contracting Entity:** Network Contracting Office 19 (NCO 19), Department of Veterans Affairs, 6162 S. Willow Drive, Suite 300, Greenwood Village, CO 80111. - **Place of Performance:** Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA. - **NAICS Code:** 334516 (Analytical Laboratory Instrument Manufacturing). - **Product Service Code:** Q301. - **Period of Performance:** April 1, 2027, through March 31, 2032. - **Primary Contact:** Phoebe Farmer, Contract Specialist ([email protected], 405-552-4372). **Procurement Type and Special Considerations** This notice is a Sources Sought/Request for Information (RFI) and is strictly for market research and planning. It is not a solicitation, and no contract will be awarded based on responses. The government will not reimburse any costs associated with responding to this notice. All responses must be submitted by November 25, 2026, at 16:30 CST. Respondents are required to provide a capabilities/qualifications statement, a completed market research questionnaire, and detailed information about their proposed solution, including business size status, FSS/GSA contract information (if applicable), and compliance with the Buy American Act and small business subcontracting limitations. The government is particularly interested in identifying small businesses, including those that are woman-owned, veteran-owned, HUBZone, or 8(a) certified. **Summary for Contractors** This opportunity is well-suited for manufacturers and suppliers of advanced blood bank analyzers and related consumables who can provide a comprehensive, turnkey solution that meets stringent clinical, operational, and regulatory requirements. Contractors must demonstrate the ability to deliver, install, and support a high-throughput, reliable analyzer system, ensure compatibility with manual backup methods, and provide ongoing reagent supply and system upgrades. The long-term nature of the agreement (five years) and the criticality of the services to patient care at a major VA medical center underscore the importance of proven performance, robust support infrastructure, and compliance with federal acquisition regulations. Interested parties should carefully review the requirements and submit a thorough response, including all requested documentation and a clear statement of capabilities, to the designated contracting officer by the specified deadline.